The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...

Retatrutide targets three key pathways linked to appetite, metabolism, and energy use: GLP-1, GIP, and glucagon. GLP-1 and ...

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Up to 28.7% weight loss in a 68-week late-stage trial * Reduced knee osteoarthritis pain by up to 62.6% * First ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...